Putting Patients First in Our Fight Against Chronic Kidney Disease Associated with Type 2 Diabetes

When I started my career in the pharmaceuticals industry, one of the first questions I asked myself was: “How can I have the greatest possible impact on people?” With the approval of Kerendia® (finerenone), we are so much closer to achieving our Vision, Health for all, hunger for none. I recall earlier in my career seeing the promise of Kerendia and since then witnessing scientific advances and innovations that give me hope for our future and for our patients.

I remain hopeful as we announce our latest FDA approved innovation which reduces the risk of sustained eGFR decline, kidney failure, cardiovascular death, heart attack, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated type 2 diabetes (T2D).There is a strong connection between these diseases: Approximately 34 million people in the U.S. have diabetes, and about 90 – 95 percent of those have T2D. CKD is a frequent complication arising from T2D and is also an independent risk factor for cardiovascular disease. T2D is not an equal opportunity condition. It is a serious disease that disproportionately affects minority communities. With our latest approval, we’re poised to provide a new treatment option for patients, and the potential is truly encouraging and compelling.

Bayer’s R&D team has been hard at work developing a treatment for this patient population. Together with our advocacy and alliance partners, we are committed to working as one, singularly focused team, both to educate the public about this treatment and to change the way CKD is managed in patients living with T2D.

I am proud of our commitment to cardiovascular and kidney health as we celebrate this latest FDA approval. Ultimately, our mission is to equip health care providers and patients with much needed additional treatment options, and to ensure there is a better life available for all.

It's important to note that Kerendia can cause hyperkalemia. For more information, see "Important Safety Information" in the press release above.